Pubertal onset in children with perinatal HIV infection in the era of combination antiretroviral treatment

AIDS

Volumn 27, Issue 12, 2013, Pages 1959-1970

  Williams, Paige L ^a,b   Abzug, Mark J ^c   Jacobson, Denise L ^a   Wang, Jiajia ^a   Van Dyke, Russell B ^d   Hazra, Rohan ^e   Patel, Kunjal ^a,b   Dimeglio, Linda A ^f   McFarland, Elizabeth J ^g   Silio, Margarita ^d   Borkowsky, William ^h   Seage III, George R ^a,b   Oleske, James M ⁱ   Geffner, Mitchell E ^j  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Nutrition Obesity Research Center at the University of Colorado   (United States)

^h NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^j CHILDREN S HOSPITAL LOS ANGELES   (United States)

more..

Author keywords

Antiretroviral treatment; BMI; CD4; Interval censored; Pediatrics; Protease inhibitors; Puberty; Statistics; Tanner stage; Viral load

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; ETHNICITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PERINATAL INFECTION; PRIORITY JOURNAL; PUBERTY; RNA VIRUS; SCHOOL CHILD; VIRUS LOAD;

ADOLESCENT; AGE FACTORS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; FEMALE; HIV; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; PUBERTY, DELAYED; RNA, VIRAL; UNITED STATES; VIRAL LOAD; YOUNG ADULT;

EID: 84884375186     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328361195b     Document Type: Article

References (48)

1. Sørensen K, Mouritsen A, Aksglaede L, Hagen CP, Mogensen SS, Juul A. Recent secular trends in pubertal timing: implications for evaluation and diagnosis of precocious puberty. Horm Res Paediatr 2012; 77:137-145.
2. Anderson SE, Dallal GE, Must A. Relative weight and race influence average age of menarche: results from two nationally representative surveys of US girls studied 25 years apart. Pediatrics 2003; 111:844-850.
3. Herman-Giddens ME, Slora EJ, Wasserman RC, Bourdony CJ, Bhapkar MV, Koch GG, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the pediatric research in office settings network. Pediatrics 1997; 99:505-512.
4. Herman-Giddens ME, Wang L, Koch G. Secondary sexual characteristics in boys. Estimates from the National Health and Nutrition Examination Survey III, 1988-1994. Arch Pediatr Adolesc Med 2001; 155:1022-1028.
5. Karpati AM, Rubin CH, Kieszak SM, Marcus M, Troiano RP. Stature and pubertal stage assessment in American Boys: The 1988-1994 Third National Health and Nutrition Examination Survey. J Adolesc Health 2002; 30:205-212.
6. Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 2010; 303:242-249.
7. Özen S, Darcan Ş. Effects of environmental endocrine disruptors on pubertal development. J Clin Res Pediatr Endocrinol 2011; 3:1-6.
8. Hirschfeld S. Dysregulation of growth and development in HIVinfected children. J Nutr 1996; 126:2641-2650S.
9. Isanaka S, Duggan C, Fawzi WW. Patterns of postnatal growth in HIV-infected and HIV-exposed children. Nutr Rev 2009; 67:343-359.
10. Gertner JM, Kaufman FR, Donfield SM, Sleeper LA, Shapiro AD, Howard C, et al. Delayed somatic growth and pubertal development in human immunodeficiency virus-infected hemophiliac boys: Hemophilia Growth and Development study. J Pediatr 1994; 124:896-902.
11. Kaufman FR, Gertner JM, Sleeper LA, Donfield SM, and the Hemophilia Growth and Development Study. Growth hormone secretion in HIV-positive versus HIV-negative hemophilic males with abnormal growth and pubertal development. J Acquir Immune Defic Syndr HumRetrovirol 1997; 15:137-144.
12. Mahoney EM, Donfield SM, Howard C, Kaufman F, Gertner JM, and the Hemophilia Growth and Development Study. HIVassociated immune dysfunction and delayed pubertal development in a cohort of young hemophiliacs. J Acquir Immune Defic Syndr 1999; 21:333-337.
13. De Martino M, Tovo PA, Galli L, Gabiano C, Chiarelli F, Zappa M, et al., for the Italian Register for HIV Infection in Children. Puberty in perinatal HIV-infection: a multicentre longitudinal study of 212 children. AIDS 2001; 15:1527-1534.
14. Buchacz K, Rogol AD, Lindsey JC, Wilson CM, Hughes MD, Seage GR, et al., for the Pediatric AIDS Clinical Trials Group 219 Study Team. Delayed onset of pubertal development in children and adolescents with perinatally acquired HIV infection. J Acquir Immune Defic Syndr 2003; 33:56-65.
15. Majaliwa ES, Mohn A, Chiarelli F. Growth and puberty in children with HIV infection. J Endocrinol Invest 2009; 32: 85-90.
16. Stagi S, Galli L, Cecchi C, Chiappini E, Losi S, Gattinara CG, et al. Final height in patients perinatally infected with the human immunodeficiency virus. Horm Res Paediatr 2010; 74:165-171.
17. Geffner ME, Yeh EY, Landaw EM, Scott ML, Stiehm ER, Bryson YJ, Israele V. In vitro insulin-like growth factor-1, growth hormone, and insulin resistance occurs in symptomatic human immunodeficiency virus-1 infected children. Pediatr Res 1993; 34:66-73.
18. Dimock D, Thomas V, Cushing A, Purdy JB, Worrell C, Kopp JB, et al. Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhood. Metabolism 2011; 60:874-880.
19. Tassiopoulos K, Williams PL, Seage GR, Crain M, Farley J. Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children. J Acquir Immune Defic Syndr 2008; 47:607-614.
20. Jacobson DL, Patel K, Siberry GK, Van Dyke RB, DiMeglio LA, Geffner ME, et al., for the Pediatric HIV/AIDS Cohort Study. Body fat distribution in perinatally HIV-infected and HIVexposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study (PHACS). Am J Clin Nutr 2011; 94:1485-1495.
21. Geffner ME, Patel K, Miller TL, Hazra R, Silio M, Van Dyke RB, et al., for the Pediatric HIV/AIDS Cohort Study. Factors associated with insulin resistance among children and adolescents perinatally-infected with HIV-1 in the Pediatric HIV/AIDS Cohort Study (PHACS). Horm Res Paediatr 2011; 76:386-391.
22. Viganò A, Brambilla P, Pattarino G, Stucchi S, Fasan S, Raimondi C, et al. Long-term evaluation of glucose homeostatis in a cohort of HAART-treatment HIV-infected children: a longitudinal, observational cohort study. Clin Drug Invest 2009; 29:101-109.
23. Chantry CJ, Frederick MM, Meyer WA 3rd, Handelsman E, Rich K, Paul ME, et al. Endocrine abnormalities and impaired growth in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2007; 26:53-60.
24. Lee PA, Gollenberg AL, Hediger ML, Himes JH, Zhang Z, Buck Louis GM. Luteinizing hormone, testosterone and inhibin B levels in the peripubertal period and racial/ethnic differences among boys aged 6-11 years: analyses from NHANES III, 1988-1994. Clin Endocrinol 2010; 73:744-751.
25. Dreimane D, Nielsen K, Deveikis A, Bryson YJ, Geffner ME. Effect of protease inhibitors combined with standard antiretroviral therapy on linear growth and weight gain in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 2001; 20:315-316.
26. Dreimane D, Geffner ME. Endocrinologic problems. In: Zeichner SL, Read JS,editors. Textbook of pediatric HIV care. 2nd ed. Cambridge UK: Cambridge University Press; 2006.
27. Nachman SA, Lindsey JC, Moye J, Stanley KE, Johnson GM, Krogstad PA, Wiznia AA, for the Pediatric AIDS Clinical Trials Group 377 Study Team. Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2005; 24:352-357.
28. McGrath CJ, Chung MH, Richardson BA, Benki-Nugen S, Warui D, John-Stewart GC. Younger age at HAART initiation is associated with more rapid growth reconstitution. AIDS 2011; 25:345-355.
29. Del Bianco G, Heresi G, Frederick T, Wheeling T, Bohannon B, Dominguez K, Siberry G. Onset of puberty in perinatally HIVinfected children and adolescents in the United States during the HAART era. Abstract presented at IDSA, October 2010; http://idsa.confex.com/idsa/2010/webprogram/Paper2859.html.
30. Brady MT, Oleske JM, Williams PL, Elgie C, Mofenson LM, Dankner W, Van Dyke RB, for the PACTG 219/219C Team. Declines in mortality rates and changes in causes of death in HIV-1 infected children during the HAART era. J Acquir Immune Defic Syndr 2010; 53:86-94.
31. Brogly S, Williams PL, Seage GR 3rd, Oleske JM, Van Dyke R, McIntosh K, for the PACTG 219C Team. Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice. JAMA 2005; 18:2213-2220.
32. Van Dyke RB, Patel K, Siberry GK, Burchett SK, Spector SA, Chernoff MC, et al., for the Pediatric HIV/AIDS Cohort Study. Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic response. J Acquir Immune Defic Syndr 2011; 57:165-173.
33. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976; 51:170-179.
34. Centers for Disease Control and Prevention. 1994 revised classification for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recomm Rep 1994; 43 (RR-12):1-10. http://www.cdc.gov/mmwr/preview/ mmwrhtml/00032890.htm
35. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41 (RR-17):1-19.
36. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT, Centers for Disease Control and Prevention (CDC). Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years: United States, 2008. MMWR Recomm Rep 2008; 57:1-12.
37. Kalish LA, McIntosh K, Read JS, Diaz C, Landesman SH, Pitt J, et al. Evaluation of human immunodeficiency virus (HIV) type 1 load, CD4 T cell level, and clinical class as time-fixed and time-varying markers of disease progression in HIV-1-infected children. J Infect Dis 1999; 180:1514-1520.
38. Rich KC, Fowler MG, Mofenson LM, Abboud R, Pitt J, Diaz C, et al. Maternal and infant factors predicting disease progression in human immunodeficiency virus type 1-infected infants. Women and Infants Transmission Study Group. Pediatrics 2000; 105:e8.
39. Cole SR, Napravnik S, Mugavero MJ, Lau B, Eron JJ Jr, Saag MS. Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden. Am J Epidemiol 2010; 171:198-205.
40. Euling SY, Herman-Giddens ME, Lee PA, Selevan SG, Juul A, Sorensen TIA, et al. Examination of US Puberty-Timing data from 1940 to 1994 for secular trends: panel findings. Pediatrics 2008; 121:S172.
41. Wu T, Mendola P, Buck GM. Ethnic differences in the presence of secondary sex characteristics and menarche among US girls: The Third National Health and Nutrition Examination Survey, 1988-1994. Pediatrics 2002; 110:752-757.
42. Sun SS, Schubert CM, Chumlea WC, Roche AF, Kulin HE, Lee PA, et al. National estimates of the timing of sexual maturation and racial differences among US children. Pediatrics 2002; 110:911-919.
43. Rosenfield RL, Lipton RB, Drum ML. Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index. Pediatrics 2009; 123:84-88.
44. Laue L, Cutler GB Jr. Abnormalities in growth and development. In: Pizzo PA, Wilfert CM,editors. Pediatric AIDS. 2nd ed. Baltimore MD: Williams & Wilkins; 1994.
45. Zeitler PS, Travers S, Kappy MS. Advances in the recognition and treatment of endocrine complications in children with chronic illness. Adv Pediatr 1999; 46:101-149.
46. Brogly SB, Watts DH, Ylitalo N, Franco EL, Seage GR III, Oleske J, et al. Reproductive health of adolescent girls perinatally infected with HIV. Am J Public Health 2007; 97:1047-1052.
47. Mofenson LM. Protecting the next generation: eliminating perinatal HIV-1 infection. N Engl J Med 2010; 362:2316-2318.
48. Fatti G, Bock P, Eley B, Mothibi E, Grimwood A. Temporal trends in baseline characteristics and treatment outcomes of children starting antiretroviral treatment: an analysis in four provinces in South Africa, 2004-2009. J Acquir Immune Defic Syndr 2011; 58:e60-e67.